Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

about

Serum neurofilament light chain in relapsing-remitting MS: Unchaining disease activity prediction?An Appraisal of Novel Biomarkers for Evaluating and Monitoring Neurologic Diseases: Editorial Introduction.Inflammation in CNS Neurodegenerative Diseases.

P2860

Q47148522-35DCBA40-4407-4ACC-B711-DEC6D434F62B Q49892100-BEEBC7CF-3D41-4CC1-9565-852968D096BC Q51765219-F1017EA5-B204-4E84-9C22-5FB21EB1AE0F

P2860

Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Item

http://www.wikidata.org/entity/Q38984981

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

@en

type

Item

label

Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

@en

prefLabel

Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

@en

P1476

Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

@en

P2093

Nabil K El Ayoubi

http://www.w3.org/2001/XMLSchema#string

Samia J Khoury

http://www.w3.org/2001/XMLSchema#string

P2860

MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood

Disease Biomarkers in Multiple Sclerosis

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis

Current Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple Sclerosis

Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

P2888

s13311-016-0486-7

P304

135-147

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13311-016-0486-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27757816

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

5233628

http://www.w3.org/2001/XMLSchema#string

Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

about

P2860

P2860

Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P932